Cancer Clinical Trial
Official title:
enCompass Carolina: A Social Support and Coaching Program for Cancer Caregivers
NCT number | NCT05828927 |
Other study ID # | LCCC2242 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 15, 2023 |
Est. completion date | July 1, 2025 |
This study explores the feasibility, acceptability, and preliminary efficacy of a social support intervention in cancer caregivers who live in rural communities. Cancer caregivers need support, especially when they live at a distance from healthcare centers. enCompass Carolina is a social support intervention, that supports caregivers by helping them find and use new sources of support. The purpose of this study is to test and receive feedback about the program.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | July 1, 2025 |
Est. primary completion date | July 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria Inclusion criteria for caregivers In order to participate in this study a subject must meet all of the eligibility criteria outlined below. 1. English-speaking. 2. Ability to provide written or electronic informed consent to participate in the study. 3. Subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designee. 4. Age = 18 years at the time of consent. Identify as an informal (unpaid) caregiver for a rural-dwelling adult with a stage II-IV solid tumor or any hematologic malignancy in active treatment (see eligibility criteria for patients). Inclusion criteria for subjects with cancer In order to participate in this study a subject must meet all of the eligibility criteria outlined below. 1. Their identified caregiver is enrolled in the study 2. English-speaking. 3. Ability to provide written or electronic informed consent to participate in the study. 4. Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designee. 5. Age = 18 years at the time of consent. Have a diagnosis of stage II-IV solid tumor or any hematologic malignancy receiving active treatment s, not including hormonal therapy 7. Live in a rural area according to the USDA's Rural/Urban Commuting Area (RUCA) score of >4. Exclusion Criteria Exclusion criteria for caregivers 1. Unable to complete self-report instruments due to illiteracy, neurologic illness, inability to speak or read English, or other causes; 2. Existence of another co-morbid disease, which in the opinion of the investigator, prohibits participation in the protocol; 3. Participation in the intervention development phase of this intervention. Exclusion criteria for subjects with cancer 1. Unable to complete self-report instruments due to illiteracy, neurologic illness, inability to speak or read English, or other causes; 2. Existence of another co-morbid disease, which in the opinion of the investigator, prohibits participation in the protocol; 3. Their caregiver does not enroll in the study or withdraws consent |
Country | Name | City | State |
---|---|---|---|
United States | UNC Lineberger | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
UNC Lineberger Comprehensive Cancer Center | The Duke Endowment |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Study feasibility - caregiver enrollment | Study feasibility will be measured by caregiver enrollment rates, defined as the proportion of eligible caregivers approached about the study who consent to participate. | 8 weeks | |
Primary | Study feasibility - Caregiver intervention engagement | Study feasibility will be measured by caregiver intervention engagement, defined as the proportion of enrolled caregiver subjects who receive at least one intervention visit. | 8 weeks | |
Secondary | Intervention acceptability-qualitative | Intervention acceptability will be measured using the Acceptability of the Intervention Measure (AIM) survey scores.
AIM is a survey questionnaire that includes 4 questions. Response Scale: 1 = Completely disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5 = Completely agree. Scoring Instructions: Scales can be created for each measure by averaging responses. Scale values range from 1 to 5. No items need to be reverse-coded. |
4 weeks, 8 weeks | |
Secondary | Intervention acceptability-quantitative | Intervention acceptability will be evaluated using thematic analysis of post-intervention semi-structured interviews. | 4 weeks, 8 weeks | |
Secondary | Caregiver self-efficacy | Caregiver self-efficacy will be measured using the Coping Self-Efficacy Scale (CSES).
The CSES is a 26-item measure of one's confidence in performing coping behaviour when facing life challenges. It measures the use of problem-focused coping, receiving of social support and stopping unpleasant emotions and thoughts. Scores range from not at all confident=0 to very confident=100. A score of 0 means 'extremely low self efficacy' and a score of 100 means 'extremely high self efficacy'. |
Baseline, 4 weeks, 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|